GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » InflaRx NV (NAS:IFRX) » Definitions » Selling, General, & Admin. Expense

InflaRx NV (InflaRx NV) Selling, General, & Admin. Expense : $18.99 Mil (TTM As of Mar. 2024)


View and export this data going back to 2017. Start your Free Trial

What is InflaRx NV Selling, General, & Admin. Expense?

Selling, general, & admin. expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. InflaRx NV's selling, general, & admin. expense for the three months ended in Mar. 2024 was $5.48 Mil. Its selling, general, & admin. expense for the trailing twelve months (TTM) ended in Mar. 2024 was $18.99 Mil.


InflaRx NV Selling, General, & Admin. Expense Historical Data

The historical data trend for InflaRx NV's Selling, General, & Admin. Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

InflaRx NV Selling, General, & Admin. Expense Chart

InflaRx NV Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Selling, General, & Admin. Expense
Get a 7-Day Free Trial Premium Member Only 13.33 9.62 12.92 15.19 17.58

InflaRx NV Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Selling, General, & Admin. Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.86 4.14 4.76 4.62 5.48

Competitive Comparison of InflaRx NV's Selling, General, & Admin. Expense

For the Biotechnology subindustry, InflaRx NV's Selling, General, & Admin. Expense, along with its competitors' market caps and Selling, General, & Admin. Expense data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


InflaRx NV's Selling, General, & Admin. Expense Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, InflaRx NV's Selling, General, & Admin. Expense distribution charts can be found below:

* The bar in red indicates where InflaRx NV's Selling, General, & Admin. Expense falls into.



InflaRx NV Selling, General, & Admin. Expense Calculation

Selling, General, & Admin. Expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. For instance, personnel cost, advertising, rent, communication costs are all part of SGA.

Selling, General, & Admin. Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $18.99 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


InflaRx NV  (NAS:IFRX) Selling, General, & Admin. Expense Explanation

An efficient operation keeps SGA costs low and thus has higher profit margin. The percentage of SGA relative to total revenue is an indication of how efficiently the company operates. Compare this percentage among the companies in the same industry is a good way of finding more efficient operations. A comparison of the SGA cost relative to the revenue with the historical value can also be an indication of how efficient the company has become.

Warren Buffett likes companies with consistent SGA as the percentage of gross profit.

Companies with no durable competitive advantage show wild variation in SG&A as % of Gross Profit.

If SGA is less than 30% of Gross Profit, it is fantastic. If SGA is nearing 100%, it is is in highly competitive industry.


InflaRx NV Selling, General, & Admin. Expense Related Terms

Thank you for viewing the detailed overview of InflaRx NV's Selling, General, & Admin. Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


InflaRx NV (InflaRx NV) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » InflaRx NV (NAS:IFRX) » Definitions » Selling, General, & Admin. Expense
Traded in Other Exchanges
Address
Winzerlaer Strasse 2, Jena, DEU, 07745
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its lead product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.

InflaRx NV (InflaRx NV) Headlines

From GuruFocus

InflaRx to Present at the H.C. Wainwright Global Investment Conference

By GuruFocusNews GuruFocusNews 05-27-2022

InflaRx to Present at the H.C. Wainwright Global Investment Conference

By GuruFocusNews GuruFocusNews 06-06-2022

InflaRx Announces Public Offering of Ordinary Shares

By sperokesalga sperokesalga 04-11-2023